Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » VIAP - VIA Pharmaceutical

 - UBBFriend: Email this page to someone!    
Author Topic: VIAP - VIA Pharmaceutical
atleast
Member


Icon 1 posted      Profile for atleast     Send New Private Message       Edit/Delete Post   Reply With Quote 
DD courtesy of EDWARD STEVENSON:

********************
VIA Pharmaceuticals, Inc.
750 Battery Street
Suite 330
San Francisco, CA 94111
Phone: 415-283-2200
Fax: 415-283-2201
Web Site: http://www.viapharmaceuticals.com


BUSINESS DESCRIPTION
VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the research and development of compounds for the treatment cardiovascular diseases. The company is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. Its principal product, VIA-2291, is in two concurrent Phase II clinical studies in patients with acute coronary syndrome and patients with stenosis of the carotid artery. The company has research, development, and commercialization agreements with Hoffmann-La Roche, Inc. and Hoffmann-La Roche Limited to develop and commercialize two sets of compounds, including thyroid hormone receptor mbeta agonist and diacylglycerol acyl transferase 1 metabolic disorders program. VIA Pharmaceuticals was founded in 2004 and is headquartered in San Francisco, California.


MANAGEMENT TEAM

Lawrence Cohen, CEO/President.
Lawrence K. Cohen, Ph.D. has served as President, Chief Executive Officer and a director of the Company since the consummation of the Merger on June 5, 2007, and prior to that time served as President, Chief Executive Officer and a director of privately-held VIA Pharmaceuticals, Inc. since its formation in 2004. Previously, he was the Chief Executive Officer of Zyomyx, Inc., a privately-held biotechnology company focused on protein chip technologies. Dr. Cohen joined Zyomyx in 1999 as Chief Operating Officer, where he was responsible for all internal activities, including research and development, business development, financing and operations. Dr. Cohen received a Ph.D. in Microbiology from the University of Illinois and completed his postdoctoral work in Molecular Biology at the Dana-Farber Cancer Institute and the Department of Biological Chemistry at Harvard Medical School.

Rebecca Taub, Senior Vice President of Research and Development
Rebecca A. Taub, M.D. has served as Senior Vice President of Research and Development of the Company since January 14, 2008, and prior to that time served as Vice President of Research in Metabolic Diseases of Roche Pharmaceuticals, a unit of Roche Holding Ltd. since 2004. While at Roche Dr. Taub oversaw drug discovery programs in diabetes, dyslipidemia and obesity, including target identification, lead optimization and advancement of pre-clinical candidates into clinical development. From 2000 through 2003, Dr. Taub worked at Bristol-Myers Squibb Co. and Dupont Pharmaceutical Company, which was acquired by Bristol-Myers in 2001, in a variety of positions, including executive director of CNS and obesity research. Before becoming a pharmaceutical executive, Dr. Taub served in a number of academic medicine and biomedical research positions. She was a tenured professor of genetics and medicine at the University of Pennsylvania School of Medicine from 1997 to 2001, and she remains an adjunct professor. Earlier she was an assistant professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute. She is the author of more than 120 research articles. Dr. Taub received her M.D. from Yale University School of Medicine and B.A. from Yale College.


SHARE STRUCTURE

Outstanding share count ~ 19.74M
Float ~ 17.71M
Data as per http://www.reuters.com/finance/stocks/overview?symbol=VIAP.W

Institutional holdings ~ 28%
A complete list of institutional share holders: http://www.mffais.com/viap.html

With four new positions gathered just recently, ALL FOUR, are increases in institutional holdings.
http://www.reuters.com/finance/stocks/institutionalHolders?symbol=VIAP.W


LATEST PRESS RELEASE

VIA Pharmaceuticals Licenses Drug Candidates from Roche to Expand Cardiovascular Pipeline to Include Metabolic Disease
-VIA Adds IND-Ready THR Beta Agonist and Preclinical DGAT1 Inhibitor Candidates-

SAN FRANCISCO, Dec 23, 2008 /PRNewswire-FirstCall via COMTEX/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced exclusive, worldwide licensing agreements with Roche (SWX: ROG) for two sets of compounds. The first was for Roche's thyroid hormone receptor (THR) beta agonist, a clinically ready candidate for the control of cholesterol, triglyceride levels and potential in insulin sensitization/diabetes. The second was for multiple compounds from Roche's preclinical diacylglycerol acyl transferase 1 (DGAT1) metabolic disorders program.

Under the terms of the agreements, VIA will assume control of all development and commercialization of the compounds, and will own exclusive worldwide rights for all potential indications. The agreements provide for milestone payments for development and royalties upon commercialization.

"We are pleased to significantly expand our pipeline of promising compounds with the in-licensing of these two programs. The THR beta agonist candidate and the DGAT1 program are natural fits for VIA, and build on the company's cardiovascular inflammation programs," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "We believe that these compounds address other critical underlying causes of cardiovascular disease: hyperlipidemias and metabolic disorders including diabetes. In addition, Dr. Rebecca Taub, our senior vice president of research and development, has significant experience in heading up development programs in metabolic diseases, and previously oversaw both the THR beta agonist and DGAT1 programs at Roche. We look forward to moving the THR beta agonist into clinical development."


***RECAP***

**From the (above) press release we derive a number of key elements including that of a huge deal that has been put in place and is, as of January 5th, 2009, in full throttle. These products that Via has gained control over, in terms of development and commercialization, are state-of-the-ark solutions to ongoing health crisis and terminal desease.

**There will always be a large demand, and therefore a market, for such products as healthcare is a basic human nessesity. The harsh economic times will have little toll on the success of such products, especially if they enduce favourable treatment. The idea behind the binding contract is that VIA has gained priviledge to market this WORLD-WIDE.

**Please note that some elements described above could not have been single-handedly derived from the press release (above) but were rather also rephrased as per statements and facts taken directly out of their latest 8K filing, whereby the company describes this very contract in much more detail. A copy can be attained by accessing this link: http://pinksheets.com/edgar/GetFilingHtml?FilingID=6314422

**Again, as per the 8K filing, they reflect upon this project every 30 days, that is following the initiation, which began on January 5th, 2009 (just as was mentioned above already). Therefore a press release/update on the company's standings concerning THR beta moving into clinical development stages may potentially arrive between late January and early February.

SOLUTIONS/PRODUCTS ~ state of the ark and revolutionary all at once.


About THR beta agonist
The THR beta agonist is an orally administered, small-molecule beta-selective thyroid hormone receptor agonist designed to specifically target receptors in the liver involved in metabolism and cholesterol regulation, and avoid side effects associated with thyroid hormone receptor activation outside the liver. Roche has completed preclinical studies of the THR beta agonist. These studies demonstrated a rapid reduction of non-HDL cholesterol and the drug was shown to be synergistic with statins in animal studies. VIA will investigate the possibility of using the THR beta agonist in combination with statins for the treatment of hypercholesterolemia. In addition, in animal studies insulin sensitization and glucose lowering were observed making this compound a possible treatment of patients with type 2 diabetes in combination with other diabetes medications.

About DGAT1
DGAT1 (diacylglycerol acyl transferase-1) is an enzyme that catalyzes triglyceride synthesis and fat storage. Triglycerides are the principal component of fat, which is the major repository for storage of metabolic energy in the body. Overweight and obese individuals have significantly greater triglyceride levels, making them more prone to diabetes and its associated metabolic complications. DGAT1 inhibitors are believed to be an innovative class of compounds that modify lipid metabolism. In studies of obese animals, DGAT1 inhibitors have been shown to induce weight loss and improve insulin sensitization, glucose tolerance and lipid levels. These observations suggest DGAT1 inhibitors may have the potential to treat obesity, diabetes and dyslipidemia. VIA intends to identify potential clinical candidates from the compounds in this program and determine which may be moved into further preclinical development.

Posts: 1580 | From: World | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
atleast
Member


Icon 1 posted      Profile for atleast     Send New Private Message       Edit/Delete Post   Reply With Quote 
Bay City Capital holds almost 50% of securities http://www.baycitycapital.com/
Other institutions ~ 28%

Available float ~4.1M shares

Posts: 1580 | From: World | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
atleast
Member


Icon 1 posted      Profile for atleast     Send New Private Message       Edit/Delete Post   Reply With Quote 
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, we've managed six venture funds representing $1.5 billion in capital invested in over 65 companies. Five of these funds are general life sciences funds, and one is a nutrition and agribusiness sector fund.


Our mature, cohesive team of nine partners has been working together for over six years. Our investment professionals have over 250 years of combined experience in operational, financial, and scientific roles in the life sciences industry. We have played significant leadership roles in a number of both public and private life sciences companies, including acting as founders and directors of start-up ventures as well as executive officers of both large cap pharmaceutical and biotechnology companies. The combination of our broad experience in the capital markets and access to a substantial network of scientific and industry expertise gives Bay City Capital a unique perspective and practical approach to creating and maximizing shareholder value.


We pursue a broad spectrum of investment opportunities across the various life sciences sectors and with companies at all stages of development. Through many years of experience in venture investing, our team has developed a systematic process based on thoughtful selection, comprehensive due diligence, and active investment management.

We invest in life sciences companies where our operational, financial, and scientific expertise can benefit company management. We work closely with our portfolio companies as true partners in their growth, creating value over the long term. We assist management in recruiting and retaining key management and scientific advisors, identifying product opportunities, establishing and negotiating strategic partnerships, and providing assistance with clinical trial design and execution. We provide ongoing access to a substantial network of industry and academic leaders, experienced advisors, and a significant amount of capital and other resources as needed.

Typically, we are the lead or co-lead investor and maintain board representation.


Bay City Capital’s life sciences venture capital funds (including co-investments from Pritzker Family business interests) represent approximately $1,450 million in capital invested in 55 companies:

Bay City Capital Fund I Formed in 1997 $150,000,000
Bay City Capital Fund II Formed in 1999 $200,000,000
Bay City Capital Fund III Formed in 2001 $250,000,000
Bay City Capital Fund IV Formed in 2004 $350,000,000
Bay City Capital Fund V Formed in 2007 $500,000,000


We have invested in a diverse group of life sciences companies, across all stages of the product lifecycle. Our portfolio includes companies focusing on biopharmaceuticals and drug discovery, as well as medical devices and diagnostics. Identified as opportunities based on our evaluation of market conditions and the overall competitive environment, our investments have ranged from seed investing to early, mid-, and late-stage, as well as select public investing.

Bay City Capital also serves as the Investment Advisor to the $111 million North American Nutrition and Agriculture Fund (NANAF). Formed in 1999, NANAF, along with its European and Australian sister funds, operates under the umbrella of the Gilde Food & Agribusiness Fund. NANAF invests in high potential companies that are at the forefront of developing new technologies that will benefit human health and agribusiness.

Bay City Capital also has entered into a joint venture with Birchmere Ventures whereby Bay City Capital serves as a co-sponsor of Birchmere Ventures III, representing $43 million in aggregate committed capital. Birchmere Ventures III is an early-stage life sciences and technology investment fund operating in Pittsburgh and focused on investing in companies in the Mid-Atlantic region.

The employees of Bay City Capital have also made significant personal commitments to all these investment funds and corresponding portfolio companies, with over $65 million invested to date.

 -

Posts: 1580 | From: World | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share